Abstract
Background Current guidelines recommend primary prevention statin therapy based on 10-year risk of atherosclerotic cardiovascular disease (ASCVD) assessed by the pooled cohort equations (PCE), while assessing effectiveness through low-density lipoprotein cholesterol levels. It remains uncertain whether 10-year ASCVD risk can accurately predict the mortality impact of lipid-lowering therapy.
Methods A retrospective analysis of National Health and Nutrition Examination Survey (NHANES) (III and 1999-2008) linked to the National Death Index was conducted with propensity score matching. The study included 6647 adults without lipid-lowering therapy and 2484 with lipid-lowering therapy. Cox regression models and C statistic were used to assess the association between 10-year ASCVD risk and mortality.
Results In the matched cohort with 4802 individuals with similar ASCVD risks, 10-year risk of ASCVD by PCE was comparable for predicating all-cause mortality at 10 years in the lipid-lowering therapy group (area under curve [AUC], 0.75; 95% CI 0.73-0.77) and without lipid-lowering therapy (0.74; 95% CI 0.71-0.77; P = 0.50). Similarly, PCE was comparable for predicting cardiovascular mortality at 10 years in both groups (AUC, 0.75; 95% CI 0.70-0.79 versus 0.77; 95% CI 0.73-0.80; P = 0.47). Lipid-lowering therapy was significantly associated with reduced all-cause mortality (adjusted hazard ratio [HR], 0.70; 95% CI 0.61-0.82; P < 0.01) and cardiovascular mortality (adjusted HR, 0.65; 95% CI, 0.51-0.83; P < 0.01), particularly in those with a 10-year ASCVD risk of 7.5% or higher.
Conclusions PCE provides comparable predictions of mortality in individuals with and without lipid-lowering therapy. Moreover, individuals on lipid-lowering therapy exhibited lower all-cause and cardiovascular mortality compared to those without lipid-lowering therapy but with a similar 10-year risk of ASCVD. These findings suggest that mortality risk reduction can be assessed by 10-year ASCVD risk estimated by PCE for primary prevention both prior and after treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were available from https://www.cdc.gov/nchs/nhanes/index.htm.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript